-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28th, the Insight database showed that Lepu Bio started the Phase I clinical trial of a biosimilar drug of dulaglutide for blood glucose control in patients with type 2 diabetes
From: Insight database (http://db.
GLP-1 receptor agonists are a new driving force for the rapid growth of the diabetes field in recent years, and the market size has approached half of that of insulin products
Trulicity (Trulicity) is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and injected once a week.
In addition to being approved for the treatment of type 2 diabetes, Trulicity was approved by the FDA in 2020 to reduce the risk of major adverse vascular events (MACE) in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or have multiple Cardiovascular risk factors
In China, Eli Lilly's Duyida was approved for marketing in February 2019.
From: Insight database (http://db.